High dose calcitriol may reduce thrombosis in cancer patients.
The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0.01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.
Beer
Tomasz M
TM
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA. beert@ohsu.edu
Venner
Peter M
PM
Ryan
Christopher W
CW
Petrylak
Daniel P
DP
Chatta
Gurkamal
G
Dean Ruether
J
J
Chi
Kim N
KN
Curd
John G
JG
DeLoughery
Thomas G
TG
D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D001158:Arteries; D002117:Calcitriol / Q000008:administration & dosage*; D000077143:Docetaxel; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications*; D043823:Taxoids / Q000008:administration & dosage; D013927:Thrombosis / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000517:prevention & control
D000972:Antineoplastic Agents, Phytogenic; D005343:Fibrinolytic Agents; D043823:Taxoids; D000077143:Docetaxel; D002117:Calcitriol